Platinum-Sensitive Malignant Female Reproductive System Neoplasm

Platinum-Sensitive Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07776171	Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer	not yet recruiting	Phase 2	176	Sun Yat-sen UniversityOTHER	1	Aug 20, 2026	clinicaltrials
NCT07454018	Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer	not yet recruiting	Phase 2	45	The First Affiliated Hospital of Soochow UniversityOTHER	0	Mar 6, 2026